newsfilter
← Latest News
Business Wire·

Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease

AR-15512 is a differentiated, novel, first-in-class product candidate for the treatment of the signs and symptoms of Dry Eye Disease COMET-3 is the second of three studies in the AR-15512 Registrational Phase 3 Program Aerie Pharmaceuticals, Inc.